Literature DB >> 22633641

Brown-Vialetto-Van Laere syndrome: a riboflavin-unresponsive patient with a novel mutation in the C20orf54 gene.

Anne Koy1, Frank Pillekamp, Thomas Hoehn, Hans Waterham, Dirk Klee, Ertan Mayatepek, Birgit Assmann.   

Abstract

Brown-Vialetto-Van Laere syndrome (Online Mendelian Inheritance in Man number 211530) is a neurodegenerative disorder characterized by pontobulbar palsy affecting cranial nerves (mainly VII-XII). Sensorineural deafness is often the leading sign, followed by other neurologic signs. Inheritance is often autosomal recessive, with mutations in the C20orf54 gene (Online Mendelian Inheritance in Man number 613350). Three previous patients with mutations in the C20orf54 gene and clinical signs of Brown-Vialetto-Van Laere or Fazio-Londe syndrome revealed a metabolic profile suggesting a multiple acyl-coenzyme A dehydrogenase defect. They benefited from riboflavin. We describe a 3-year-old girl with early-onset Brown-Vialetto-Van Laere syndrome and a novel mutation in the C20orf54 gene (c.989G>T). On T(2)-weighted imaging, increased signal intensity of the vestibular nuclei bilaterally, the pedunculus cerebellaris superior and the central tegmental tract were observed during acute clinical deterioration. Her metabolic profile was normal. Trials with steroids, immunoglobulins, and riboflavin produced no effect. The patient recovered slowly during subsequent months, with residual deficits. Brown-Vialetto-Van Laere syndrome should be considered in patients with sensorineural hearing loss and pontobulbar palsy. Patients should be screened for riboflavin deficiency and a therapy with riboflavin may provide effective treatment in some affected patients.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22633641     DOI: 10.1016/j.pediatrneurol.2012.03.008

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  7 in total

1.  SLC52A3, A Brown-Vialetto-van Laere syndrome candidate gene is essential for mouse development, but dispensable for motor neuron differentiation.

Authors:  Atsushi Intoh; Naoki Suzuki; Kathryn Koszka; Kevin Eggan
Journal:  Hum Mol Genet       Date:  2016-03-13       Impact factor: 6.150

2.  Disruption of Slc52a3 gene causes neonatal lethality with riboflavin deficiency in mice.

Authors:  Hiroki Yoshimatsu; Atsushi Yonezawa; Kaori Yamanishi; Yoshiaki Yao; Kumiko Sugano; Shunsaku Nakagawa; Satoshi Imai; Tomohiro Omura; Takayuki Nakagawa; Ikuko Yano; Satohiro Masuda; Ken-Ichi Inui; Kazuo Matsubara
Journal:  Sci Rep       Date:  2016-06-08       Impact factor: 4.379

3.  Antioxidant Amelioration of Riboflavin Transporter Deficiency in Motoneurons Derived from Patient-Specific Induced Pluripotent Stem Cells.

Authors:  Chiara Marioli; Valentina Magliocca; Stefania Petrini; Alessia Niceforo; Rossella Borghi; Sara Petrillo; Piergiorgio La Rosa; Fiorella Colasuonno; Tiziana Persichini; Fiorella Piemonte; Keith Massey; Marco Tartaglia; Sandra Moreno; Enrico Bertini; Claudia Compagnucci
Journal:  Int J Mol Sci       Date:  2020-10-07       Impact factor: 5.923

Review 4.  The Brown-Vialetto-Van Laere and Fazio Londe syndrome revisited: natural history, genetics, treatment and future perspectives.

Authors:  Annet M Bosch; Kevin Stroek; Nico G Abeling; Hans R Waterham; Lodewijk Ijlst; Ronald J A Wanders
Journal:  Orphanet J Rare Dis       Date:  2012-10-29       Impact factor: 4.123

Review 5.  The human flavoproteome.

Authors:  Wolf-Dieter Lienhart; Venugopal Gudipati; Peter Macheroux
Journal:  Arch Biochem Biophys       Date:  2013-03-15       Impact factor: 4.013

Review 6.  Clinical and genetic diversity of SMN1-negative proximal spinal muscular atrophies.

Authors:  Kristien Peeters; Teodora Chamova; Albena Jordanova
Journal:  Brain       Date:  2014-06-25       Impact factor: 13.501

Review 7.  Clinical presentation and outcome of riboflavin transporter deficiency: mini review after five years of experience.

Authors:  Bregje Jaeger; Annet M Bosch
Journal:  J Inherit Metab Dis       Date:  2016-03-14       Impact factor: 4.982

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.